靶向TNF/IAP通路与抗CD3免疫治疗在T细胞急性淋巴细胞白血病中协同作用
该研究在T-ALL患者来源异种移植模型中,发现抗CD3单抗诱导TNFα、LTα及NF-κB信号通路组分表达;依那西普增强抗CD3抗白血病作用,而SMAC模拟物birinapant通过抑制cIAP1/2与抗CD3协同抑制白血病进展并改善小鼠生存,呈RIPK1依赖方式。
要点
- 抗CD3单抗治疗T-ALL可诱导TNFα/LTα及NF-κB信号通路组分表达。
- 依那西普增强抗CD3抗白血病作用,提示TNF/TNFR生存通路干扰TCR诱导的白血病细胞死亡。
- birinapant抑制cIAP1/2,以RIPK1依赖方式与抗CD3协同抑制白血病扩增并改善小鼠生存。
核心结论
- 结果提倡使用TNFα/LTα抑制剂或birinapant/其他SMAC模拟物来改善T-ALL的抗CD3免疫治疗。
研究设计与样本
- 研究在T-ALL患者来源异种移植模型中进行,采用大规模转录组分析及体内实验。
主要发现
- 抗CD3单抗治疗的T-ALL中TNFα、LTα及「TNFα经NF-κB信号」通路多个组分显著表达。
- 依那西普作为TNFα/LTα的诱饵受体,在体内增强抗CD3的抗白血病特性。
- birinapant抑制cIAP1/2,以RIPK1依赖方式与抗CD3协同损害白血病扩增并改善小鼠生存。
关键数值与推荐
- 儿童T-ALL当前强化化疗方案总生存率约85%,成人低于50%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Current treatments, based on intensive chemotherapy regimens provide overall survival rates of ∼85% in children and <50% in adults, calling the search of new therapeutic options. We previously reported that targeting the T-cell receptor (TCR) in T-ALL with anti-CD3 (αCD3) monoclonal antibodies (mAbs) enforces a molecular program akin to thymic negative selection, a major developmental checkpoint in normal T-cell development; induces leukemic cell death; and impairs leukemia progression to ultimately improve host survival. However, αCD3 monotherapy resulted in relapse. To find out actionable targets able to re-enforce leukemic cells' vulnerability to αCD3 mAbs, including the clinically relevant teplizumab, we identified the molecular program induced by αCD3 mAbs in patient-derived xenografts derived from T-ALL cases. Using large-scale transcriptomic analysis, we found prominent expression of tumor necrosis factor α (TNFα), lymphotoxin α (LTα), and multiple components of the "TNFα via NF-κB signaling" pathway in anti-CD3-treated T-ALL. We show in vivo that etanercept, a sink for TNFα/LTα, enhances αCD3 antileukemic properties, indicating that TNF/TNF receptor (TNFR) survival pathways interferes with TCR-induced leukemic cell death. However, suppression of TNF-mediated survival and switch to TNFR-mediated cell death through inhibition of cellular inhibitor of apoptosis protein-1/2 (cIAP1/2) with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant synergizes with αCD3 to impair leukemia expansion in a receptor-interacting serine/threonine-protein kinase 1-dependent manner and improve mice survival. Thus, our results advocate the use of either TNFα/LTα inhibitors, or birinapant/other SMAC mimetics to improve anti-CD3 immunotherapy in T-ALL.
引用
- Ávila Ávila A, Nuantang K, Oliveira ML, et al. Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia. Blood. 2024. PMID: 38437728. doi:10.1182/blood.2023022455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。